Biontech Stock Analysis

BNTX -  USA Stock  

USD 154.54  6.16  3.83%

The big decline in price over the last few months for Biontech Se ADR could raise concerns from investors as the firm it trading at a share price of 154.54 on 2,473,667 in volume. The company directors and management failed to add value to investors and positioning the firm supply of money to exploit market volatility in December. However, diversifying your holdings with Biontech Se ADR or any similar stocks can still protect your portfolios during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 6.47. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Biontech partners.
Continue to Trending Equities.

Biontech Stock Analysis 

 
Refresh
The Biontech stock analysis report makes it easy to digest most publicly released information about Biontech and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Biontech Stock analysis module also helps to analyze the Biontech price relationship with some important fundamental indicators such as market cap and management efficiency.

Biontech Stock Analysis Notes

About 67.0% of the company shares are held by company insiders. The book value of Biontech was currently reported as 35.65. The company recorded earning per share (EPS) of 31.54. Biontech Se ADR had not issued any dividends in recent years. BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany. Biontech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 2800 people. For more info on Biontech Se ADR please contact the company at 49 6131 9084 0 or go to https://www.biontech.de.

Biontech Quarterly Cost of Revenue

1.21 BillionShare

Biontech Se ADR Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Biontech's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Biontech Se ADR or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Biontech Se ADR generated a negative expected return over the last 90 days
Biontech Se ADR has high historical volatility and very poor performance
Biontech Se ADR has high likelihood to experience some financial distress in the next 2 years
Biontech Se ADR has a poor financial position based on the latest SEC disclosures
About 67.0% of the company shares are held by company insiders
Latest headline from www.entrepreneur.com: BioDelivery Stock Up on Raised Guidance for 2021 - Entrepreneur

Biontech Se ADR Upcoming and Recent Events

Earnings reports are used by Biontech to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Biontech previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report29th of March 2022
Next Earnings Report9th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End29th of March 2022
Last Quarter Report30th of September 2021
Last Earning Announcement31st of December 2020

Biontech Largest EPS Surprises

Earnings surprises can significantly impact Biontech's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2019-11-14
2019-09-30-0.1916-0.15430.037319 
2020-05-12
2020-03-31-0.3003-0.26040.039913 
2020-08-11
2020-06-30-0.3701-0.4458-0.075720 
View All Earnings Estimates

Biontech SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Biontech prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Biontech investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Biontech Se ADR specific information freely available to individual and institutional investors to make a timely investment decision.

Biontech Thematic Classifications

In addition to having Biontech stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Biotech IdeaBiotech
Biotechnology and pharmaceuticals production and services

Biontech Market Capitalization

The company currently falls under 'Large-Cap' category with current market capitalization of 36.62 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Biontech's market, we take the total number of its shares issued and multiply it by Biontech's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Biontech Profitablity

Biontech's profitability indicators refer to fundamental financial ratios that showcase Biontech's ability to generate income relative to its revenue or operating costs. If, let's say, Biontech is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Biontech's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Biontech's profitability requires more research than a typical breakdown of Biontech's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of 54.34 %, which can signify that it executes well on its competitive strategies and has good control over its expenditures. This is very large. Similarly, it shows Operating Margin (OM) of 74.25 %, which suggests for every 100 dollars of sales, it generated a net operating income of 0.74.
Last ReportedProjected for 2022
Return on Average Assets 0.0126  0.0136 
Return on Average Equity 0.0162  0.0166 
Return on Invested Capital(0.30) (0.32) 
Return on Sales(0.19) (0.21) 

Management Efficiency

The entity has return on total asset (ROA) of 81.62 % which means that it generated profit of $81.62 on every $100 spent on asset. This is very large. Similarly, it shows return on stockholders equity (ROE) of 155.47 %, meaning that it created $155.47 on every $100 dollars invested by stockholders. Biontech management efficiency ratios could be used to measure how well biontech se adr manages its routine affairs as well as how well it operates its assets and liabilities. Biontech Return on Average Assets are fairly stable at the moment as compared to the past year. Biontech reported Return on Average Assets of 0.0126 in 2021. Return on Average Equity is likely to rise to 0.0166 in 2022, whereas Return on Invested Capital is likely to drop (0.32)  in 2022. Biontech Total Assets are fairly stable at the moment as compared to the past year. Biontech reported Total Assets of 2.67 Billion in 2021. Current Assets is likely to rise to about 2.1 B in 2022, whereas Goodwill and Intangible Assets are likely to drop slightly above 160.4 M in 2022.
Last ReportedProjected for 2022
Book Value per Share 6.96  7.51 
Enterprise Value over EBIT(161.10) (173.82) 
Enterprise Value over EBITDA(310.06) (334.54) 
Price to Book Value 9.95  11.05 
Tangible Assets Book Value per Share 10.93  8.67 
Enterprise Value20.3 B17.9 B
Tangible Asset Value2.5 B2.7 B

Technical Drivers

As of the 27th of January, Biontech shows the mean deviation of 4.68, and Risk Adjusted Performance of (0.07). Biontech Se ADR technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to interpolate and analyze data for nineteen technical drivers for Biontech Se ADR, which can be compared to its rivals. Please confirm Biontech Se ADR coefficient of variation, maximum drawdown, as well as the relationship between the Maximum Drawdown and skewness to decide if Biontech Se ADR is priced correctly, providing market reflects its regular price of 154.54 per share. Given that Biontech has jensen alpha of (0.70), we suggest you to validate Biontech Se ADR's prevailing market performance to make sure the company can sustain itself at a future point.

Biontech Se ADR Price Movement Analysis

Illegal number of arguments. The output start index for this execution was zero with a total number of output elements of zero. The Triangular Moving Average shows Biontech double smoothed mean price over a specified number of previous prices (i.e., averaged twice). View also all equity analysis or get more info about triangular moving average overlap studies indicator.

Biontech Predictive Daily Indicators

Biontech intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Biontech stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Biontech Forecast Models

Biontech time-series forecasting models is one of many Biontech's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Biontech's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Biontech Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Biontech stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Biontech shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Biontech. By using and applying Biontech Stock analysis, traders can create a robust methodology for identifying Biontech entry and exit points for their positions.
Last ReportedProjected for 2022
EBITDA Margin(0.10) (0.11) 
Gross Margin 1.01  1.03 
Profit Margin 0.0368  0.0397 
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany. Biontech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 2800 people.

Current Biontech Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Biontech analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Biontech analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
281.6Hold10Odds
Biontech Se ADR current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Biontech analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Biontech stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Biontech Se ADR, talking to its executives and customers, or listening to Biontech conference calls.
Biontech Analyst Advice Details

Biontech Stock Analysis Indicators

Biontech Se ADR stock analysis indicators help investors evaluate how Biontech stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Biontech shares will generate the highest return on investment. By understating and applying Biontech stock analysis, traders can identify Biontech position entry and exit signals to maximize returns.
Quick Ratio2.65
Fifty Two Week Low90.29
Revenue Growth8,918.20%
Shares Short Prior Month3.19M
Average Daily Volume Last 10 Day3.04M
Average Daily Volume In Three Month3.43M
Shares Percent Shares Out0.89%
Gross Margins76.25%
Forward Price Earnings3.81
Float Shares77.89M
Fifty Two Week High464.00
Enterprise Value To Ebitda5.11
Fifty Day Average260.01
Two Hundred Day Average259.85
Enterprise Value To Revenue3.82
Continue to Trending Equities. Note that the Biontech Se ADR information on this page should be used as a complementary analysis to other Biontech's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.

Complementary Tools for Biontech Stock analysis

When running Biontech Se ADR price analysis, check to measure Biontech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biontech is operating at the current time. Most of Biontech's value examination focuses on studying past and present price action to predict the probability of Biontech's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Biontech's price. Additionally, you may evaluate how the addition of Biontech to your portfolios can decrease your overall portfolio volatility.
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Go
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Go
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Go
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Go
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
Global Correlations
Find global opportunities by holding instruments from different markets
Go
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Is Biontech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biontech. If investors know Biontech will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biontech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Biontech Se ADR is measured differently than its book value, which is the value of Biontech that is recorded on the company's balance sheet. Investors also form their own opinion of Biontech's value that differs from its market value or its book value, called intrinsic value, which is Biontech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biontech's market value can be influenced by many factors that don't directly affect Biontech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biontech's value and its price as these two are different measures arrived at by different means. Investors typically determine Biontech value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biontech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.